10 Gastroenterology / Hepatology CRO and CDMO vendors

What kind of CRO work does a Gastroenterology / Hepatology program need?

GI and liver programs lean hard on disease models that behave differently from a generic toxicology line, so the first thing you are buying is biology that actually mirrors the clinic. For inflammatory bowel disease, that usually means chemically induced colitis (DSS or TNBS), adoptive-transfer or IL-10 knockout models, and increasingly patient-derived intestinal organoids and gut-on-a-chip systems that let you read barrier function and inflammation without an animal. For liver, the work splits between fibrosis (CCl4, bile-duct ligation, thioacetamide), diet-induced steatohepatitis for NASH and the newer MASH naming, and precision-cut liver slices or primary hepatocyte work for mechanism and metabolism. Microbiome programs add a layer most CROs are not set up for: germ-free and gnotobiotic husbandry, 16S and shotgun sequencing, metabolomics on short-chain fatty acids and bile acids, and the bioinformatics to make sense of it.

Discovery and preclinical services here look familiar on the surface (target validation, assay development, screening, PK/PD, GLP toxicology) but the readouts are indication-specific. You care about histology scored by a GI pathologist (Geboes or Nancy index for colitis, NAS and fibrosis staging for liver), gut permeability assays, fecal calprotectin and lipocalin, transaminases and liver-function panels, and where relevant the FXR, TGR5, and bile-acid pathways that drive a lot of current hepatology chemistry. A vendor that has only run oncology efficacy work will not know which of these endpoints a reviewer expects.

On the clinical side, gastroenterology and hepatology are recruitment-heavy. Trials hinge on endoscopy with central reading, biopsy collection and handling, and biomarker logistics that a generalist site network often fumbles. IBD studies need confirmed Crohn's or ulcerative colitis patients with scored endoscopic disease at baseline; NASH and cirrhosis trials need biopsy-confirmed or, increasingly, FibroScan and MRI-PDFF-staged patients, which narrows the eligible pool sharply. A CRO with real GI and hepatology sites, hepatologist investigators, and central endoscopy reading experience will save you months that a broad-spectrum CRO spends learning the disease.

How do you choose a CRO for Gastroenterology / Hepatology?

The honest filter is whether the group has done your specific GI or liver work before, not whether they have a slide that says they cover the therapeutic area. A team that runs flawless DSS colitis may have never staged a fibrosis model, and a clinical CRO with strong oncology sites can be weak on IBD recruitment. Score two or three vendors against the same written scope using the checklist below, and ask to speak with the scientists or medical monitor who would actually run your program.

• Therapeutic-area experience: ask for named GI and hepatology programs they have run (IBD, NASH/MASH, fibrosis, cirrhosis, GI motility), and confirm the people on your project did that work, not a different team at the same company.
• Relevant disease models or patient access: for preclinical, confirm they run the specific model you need (DSS, TNBS, adoptive transfer, CCl4, bile-duct ligation, diet-induced NASH, gnotobiotic microbiome work) with established historical control data; for clinical, confirm sites and investigators that recruit confirmed IBD or biopsy/elastography-staged liver patients.
• Endpoint and pathology depth: check that histology is read by a GI or liver pathologist using accepted scoring (Geboes, Nancy, NAS, fibrosis stage), and that they handle indication-specific biomarkers (calprotectin, transaminases, bile acids, FibroScan, MRI-PDFF) correctly.
• Regulatory track record: ask for IND-enabling packages and submissions in GI or hepatology specifically, GLP status for the tox work, and familiarity with FDA and EMA expectations for these indications (the MASH endpoint guidance, for instance, has shifted recently).
• Data quality and traceability: look for documented SOPs, qualified assays with performance data, central reading for endoscopy and imaging, clean audit-ready data capture, and reference programs you can actually call.
• Capacity and lead time: germ-free suites, biopsy-capable sites, and central endoscopy readers are genuinely scarce, so confirm the real queue and turnaround rather than the brochure timeline, since a booked specialist can be slower than an open generalist who then has to learn the disease.